Monthly Newsletter

Dutch Software Company GENALICE today announced at the 14^th Bio-IT World Conference & Expo that it has started discussions with Intel® about a product development as well as a product delivery partnership.

On 12/12 last year, GENALICE launched its groundbreaking DNA processing software; GENALICE MAP. On a simple dual Intel® Xeon® E5 server the company was capable to map the short reads of 42 complete human and 42 full tomato genomes within 24 hours. The software is designed to optimally make use of the modern hardware architecture of these commodity Intel processors.

Jos Lunenberg, GENALICE’s Chief Business Officer, comments: “It was impressive to see how well the Intel® Xeon® processors perform, when properly coded software is built around it. We now have agreed to team-up with Intel to even further improve their commodity processor to process DNA data.”

“There’s great analogy with video data processing, which started on Big Iron to end-up on a small chip,” adds Hans Karten, GENALICE’s CEO/CTO.  “We are extremely excited to start this partnership, as this will allow us to further optimize this hardware/software combination to meet the big data challenge in medicine. Together we can now offer healthcare providers a bridge to personalized medicine by processing the sequenced full genome data of a patient’s cancer faster, better and more cost-effective than ever before. 

In this partnership Intel® will also become the main hardware supplier of GENALICE. Its product MAP is delivered to customer in a turn-key appliance, the GENALICE VAULT, which includes workflow management, tracking and real-time monitoring software, an embedded Oracle database and a storage solution. 

About GENALICE

GENALICE is a privately owned, innovative software company, based in the Netherlands. It designs and builds groundbreaking software solutions for cost effective and accurate DNA data processing on commodity hardware. Its mission is to save lives and improve the quality of life of people with complex DNA-related diseases, such as cancer. With state of the art technology GENALICE wants to make an important contribution to improved drug development, diagnosis and treatment.

more about genalice